By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Where the characters work through the week's evidence.

How the tracks work together: The Root Room is where you watch a bad move actually work on somebody, and where misinformation starts with our version of Black Box Warnings. It shows you how to stay in the room and have a hard health conversation, using the same evidence Plain Talk breaks down and The Informed sources.

The Room You Have Never Heard Of

Somewhere between a drug working in a laboratory and that drug reaching your pharmacy, there are hundreds of meetings. Outside of a small portion where patient advocacy groups weigh in on protocol design, patients aren't a part of the meetings. Some of those study planning meetings decide which parts of the country the trial will open in.

Which means they decide who gets studied, and whose bodies the dose printed on the label will be worked out from.

The meeting topic is called site selection, and almost nobody outside the industry knows it happens. It's not in the drug ads or news coverage. It's not in the consent form you would sign if you ever joined a trial, because by the time anyone hands you a consent form this meeting finished likely over 4 months ago.

It's not being hidden, it's just boring, and it happens before there's anything for a press release to report. So it stays invisible, and it's one of the highest leverage rooms in the whole pipeline.

Today's Root Room sits in on one of those strategy meetings.

Two of our helpers are watching it with you. Sam the Skeptic, who asks how do we know, and never lets anyone skip that question, including us. And Rooty the Researcher, who brings the receipts. Sam asks and Rooty answers. That's how this works every week.

Six Percent

"6%," Yusuf says, and puts the map up. Yusuf runs feasibility. As a feasibility strategist, his job is to work out which countries and which hospitals a study can realistically open in, and to say so before anyone commits. He's the closest thing this room has to a scout. He looks at where and how present the illness/disease for the clinical trial is in several countries to see which make the most sense to go to. He sees how much competition there is with other similar trials, and if there are good research sites to find and enroll the patients.

"Somebody went back through 341 trials that got drugs approved and checked who was actually in them. 6% matched the country. Project management wants a diversity assessment on this site list before we commit, and honestly, look at the map. We'd deserve the question."

Priya, the clinical trial manager, has a timeline open and does not look up from it. She works for the contract research organization the drug company hired to actually run this study, and her job, stated plainly, is to get the trial enrolled on schedule. Not fairly- on schedule. Remember that, because it matters in a minute.

"How many sites, and how fast?" she asks.

"Twelve. And the twelve that enroll fastest are not the twelve that get you the population." Replies Yusuf. "If we take your twelve, we're heavy in four metros and we have almost nothing in the Delta, nothing in the Rio Grande Valley, and one site covering an area the size of a small country." Yusuf lets that sit. "If we swap three of them, the mix looks a lot more like the census. And we're probably six to eight weeks slower to last patient in."

Some key time points on any clinical trial are First Site Activated (FSA), First Patient Screened (FPS; when the first patient consents to the trial), First Patient In (FPI; first actual day of enrollment), and Last Patient In (LPI; the fulfillment of the sample size needed to meet the study's goals). LPI is a huge driver for the cost of a study. If it's not met in time, the cost of the study goes up, sometimes by hundreds of thousands of dollars a month.

"Six to eight weeks." Priya writes it down. "I have a timeline that already assumes nothing goes wrong, and something always goes wrong."

"I know." Replied Yusuf.

"I'm not saying no." She finally looks up. "I'm saying somebody above both of us has to decide that six weeks is worth it, in writing, because when we're behind in month nine it's going to be my name on the slide, and I'd like the reason to be on a slide too because the diversity requirement is important as well."

Sam the Skeptic leans toward Rooty. "I thought this room was going to be the villain's lair, honestly."

"Some weeks it might be," Rooty says. "This isn't one of them. Watch what actually just happened. Nobody said let's leave anyone out. One person has a map and one person has a calendar, and the calendar is the thing with a number on it."

"Last week you had me watching them try to skip the animal step," Sam says. "New Approach Methodologies, the Modernization Act, more than nine in ten drugs that look fine in an animal and fail in a person. This is the same argument one step later, isn't it."

"Same question, later in the pipeline. Last week was what you test it on. This week is who." Rooty tips his head at the map. "Picture that enrollment data as a group photo. The FDA looks at the photo and decides the drug's safe for everyone in the room. This meeting, right here, is where somebody decides who's standing close enough to the camera to be in it."

"Is that normal?"

"More normal than you'd think, and it's why the fix has to live here and not later. Once the sites are picked, the photo is mostly taken. But here's the part people miss. Before 1993, nobody was legally required to include women, or members of minority groups, in NIH funded research at all. It took an act of Congress to make that not optional, and the law says in writing that cost isn't a permissible reason to leave people out. That line exists because cost was the standing excuse."

"So it's fixed now."

"Fixed is the wrong word. Required, tracked, reported on, yes. Finished, no. Women still get more bad drug reactions than men on average, and part of that traces back to doses worked out from data that skewed male for decades. That's not a scandal from last year. That's a hole somebody's still filling in."

"Is it only women?"

"No, and that's the part that keeps getting left out." Rooty pulls the numbers up. "Take cystic fibrosis. There's a drug called Trikafta that genuinely changed what that diagnosis means for a lot of families. Look at who was in the two trials that got it approved. Five hundred and ten people. Four hundred and seventy three of them white. Four Black."

"Four."

"Four. And the consequence doesn't stop when the trial ends, which is the bit people miss. These drugs are approved for specific genetic variants, and the label lists the variants somebody actually studied. Go through the patient registry and about ninety two percent of white patients with cystic fibrosis have a variant that qualifies them for one of these drugs. For Black patients it's about seventy."

"So it works worse for them."

"No. That's the thing to get right, and it's the thing almost everybody gets wrong." Rooty turns to face Sam directly. "The drug doesn't know anything about race. Race isn't a biological category, it's a social one. What's actually going on is that the variants more common in people of African ancestry are less likely to have been studied well enough to make it onto a label. It isn't a difference in how the medicine works. It's a difference in whose genetics got looked at."

"And nobody chose that either."

"Nobody chose it in any single meeting. It got chosen four people at a time, in rooms like this one, for twenty years."

Sam is quiet for a second. "Who else?"

"Almost everyone, eventually. Across three hundred and two large cancer trials, the people enrolled averaged six and a half years younger than the people who actually get those cancers, and that gap has been widening. Pregnant women are close to invisible, fewer than one in ten drugs approved since 1980 have enough information to say whether they cause birth defects. And anyone with kidney trouble, or liver trouble, or two conditions at once, tends to get filtered out by the protocol before anybody even picks a site."

"That's most people I know."

"That's most people, full stop. And the further you sit from the middle of that photograph, the more of your dose is an educated guess."

Yusuf is still on the map. "There's a woman two hours from our nearest pin with this diagnosis. She's not in our screening pool, because it's a hundred and ten miles each way and she works Tuesdays. She'll take this drug though, once it's approved. Whether we studied anyone like her or not."

Priya doesn't disagree. She just adds a line to the timeline and slides it across.

"Then get me the three swaps by Thursday and I'll take the six weeks up to leadership."

The Move to Keep

Ask for the date. Any claim built on "always," "never," or "still" is a claim about right now resting on evidence from some specific then. Ask when it was last true, and ask what's happened since. Do it to the claim that annoys you and to the claim that comforts you. Otherwise you're not checking, you're shopping.

Sam the Skeptic: "You're not checking. You're shopping."

Take This One With You

Here's the part to actually use. You will hear both halves of this in the wild, probably this month, and most people can only answer one of them. You can answer both, in a sentence, without calling anyone a liar.

When somebody says trials have never studied people like us:

"That was true, and it took a law to change it. Women weren't required to be included in federally funded research until 1993. It's better now and it's still not fixed, six percent of recent trials actually matched the country. Both of those are true at once."

When somebody says that's all been handled, there are requirements now:

"There's a law, and the rulebook that was supposed to explain how to follow it never got finished. It's still sitting in draft. So the requirement is real and the enforcement isn't there yet."

Notice what neither of those does. Neither one tells the other person they're stupid, and neither one asks them to switch sides. Both hand them a date and let them do the rest.

That's the whole method. You are not trying to win. You are trying to put a date back on a claim that had one removed, and a person who accepts a date from you today will accept another one from you next year.

Next issue: another room you were never told about, and this one can stop a trial dead while it's running, without telling you it did.

Send this to one person

Not "someone who should know." One person. The friend who takes a sleeping pill. The sister who got told her dose was standard. Wednesday's Plain Talk is the one that names the drug, and it's free at RootToRx.com.

Want to practice the move before you need it? Stay in the Room is our two minute game on holding a hard health conversation without either person walking out. Free, no signup, at openlabelmedia.com/games.

You just watched the people behind your medicine do the work. Send this to someone who needs to trust them, and collect a Series 1 card while you're at it. Every share really helps this newsletter grow.

New here? Root to Rx runs three pieces a week. Monday you watch a real health claim try to work on someone. Wednesday you get the tools to run it yourself. Thursday you get the full evidence so you can check my work. Written by a clinical researcher, free, at RootToRx.com.

Thursday's The Informed doesn't arrive on its own. It's the same week's story with the receipts attached: every figure sourced, every citation ranked by how much weight it can actually hold, and the questions I couldn't close listed as open rather than quietly dropped. A full evidence dossier every week isn't what everyone signed up for, so it's opt-in rather than automatic. If you want it, click Manage preferences at the bottom of this email, sign in with your address, and tick The Informed (Thursdays). Ten seconds, it saves on its own, and you can switch it back off the same way.

For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.

Instagram: instagram.com/roottorx | LinkedIn: linkedin.com/company/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | Subscribe: RootToRx.com

You are receiving this because you subscribed at roottorx.com.

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States